The agreement for the use of NuProbe’s NGS panel will support the accelerated development of Angle’s pan-cancer assay.

Market Growth Driven by Advancements in Genomic Research, Rising Demand for Personalized Medicine, and Key Applications in ...

Results from a new University of Kentucky Markey Cancer Center study show that molecular tumor boards can play an important ...

Most patients with advanced prostate cancer or urothelial cancer are not undergoing next-generation sequencing, a new study suggests.

Metagenomic sequencing uses next generation sequencing (NGS) to rapidly identify and analyze microbial community diversity and understand the role of constituent species. Our proprietary microbial ...

ANGLE ANNOUNCES NEXT GENERATION SEQUENCING ASSAY AGREEMENT WITH NUPROBE. Option for exclusive licence to highly sensitive NGS assay for use with CTCs and dual analysis of CTCs wit ...

QIAGEN N.V.QGEN and Becton, Dickinson and Company or BD’s BDX joint venture, PreAnalytiX GmbH, recently launched the PAXgene ...

CleanNGS Dx is CleanNA’s third CE-IVD compliant product launched over the course of a year, after the Clean Cell Free DNA Kit ...

Burning Rock Biotech Limited (NASDAQ: BNR) (the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, ...

ANGLE plc has signed an agreement with NuProbe USA to use its pan-cancer next generation sequencing panel. NuProbe has granted ANGLE plc an option for an exclusive global license to the NGS panel ...

According to a Schedule 13D filed on September 19, 2024 with the U.S. Securities and Exchange Commission (the “SEC”) disclosing Concentra’s proposal, Tang Capital is the controlling stockholder of ...